Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD 4) receptor antagonist, in patients with chronic asthma
TF Reiss, LC Altman, P Chervinsky, A Bewtra… - Journal of Allergy and …, 1996 - Elsevier
BACKGROUND: Cysteinyl leukotrienes mediate signs and symptoms of asthma. In a double-
blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene
(LTD 4) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and
clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled
corticosteroids). METHODS: Twenty-nine nonsmoking patients with asthma (15 treated
concomitantly with inhaled corticosteroids) with FEV 1 percent predicted values between …
blind, placebo-controlled, crossover study, a new potent and specific cysteinyl leukotriene
(LTD 4) receptor antagonist, montelukast (MK-0476), was evaluated for tolerability and
clinical efficacy in patients with chronic asthma (receiving and not receiving inhaled
corticosteroids). METHODS: Twenty-nine nonsmoking patients with asthma (15 treated
concomitantly with inhaled corticosteroids) with FEV 1 percent predicted values between …